Archive for November, 2005
November 30th, 2005. Carcinoma of the jejunum with multideposit peritoneal seeding, resection and intraperitoneal chemotherapy
This condition is reviewed along with the rationale for IPC. keywords: Carcinoma, jejunum, multideposit peritoneal seeding, resection, intraperitoneal, chemotherapy.
November 28th, 2005. Extended Surgical Staging for Potentially Resectable Malignant Pleural Mesothelioma
Conclusions: Extended surgical staging defines an important subset of patients with unresectable MPM not identified by imaging. Because of the potential morbidity associated with extrapleural pneumonectomy, we advocate that extended surgical staging be performed in all patients with MPM before resection.
November 28th, 2005. Ribonucleases as a Novel Pro-Apoptotic Anticancer Strategy: Review of the Preclinical and Clinical Data for Ranpirnase
Phase II tumor-specific trials investigated the activity of ranpirnase in malignant mesothelioma, breast cancer, non-small cell lung cancer, and renal cell cancer. A Phase III randomized study in malignant mesothelioma patients compares the combination of ranpirnase plus doxorubicin to doxorubicin monotherapy.
November 25th, 2005. Clear cell mesothelioma of the testis with deciduoid areas–a case report
Awareness of this variant is required to avoid misdiagnosis and treatment as either metastasis from a renal cell carcinoma or as a germ cell tumor. A diagnosis of mesothelioma must be ruled out in elderly patients with epithelial-looking tumor especially if the serum germ cell tumor markers are within normal range.
November 25th, 2005. Inhibition of the Met Receptor in Mesothelioma
Conclusions: Taken together, these findings suggest that inhibition of the Met receptor may be an effective therapeutic strategy for patients with MPM and provides a mechanism, the presence of a HGF/Met autocrine loop, by which to select patients for PHA-665752 treatment.
November 25th, 2005. The global burden of disease due to occupational carcinogens
Conclusions: Occupational carcinogens are an important cause of death and disability worldwide. Am. J. Ind. Med. 48:419-431, 2005. © 2005 Wiley-Liss, Inc.
November 22nd, 2005. Prognostic significance of Bax and Fas Ligand in erionite and asbestos induced Turkish malignant pleural mesothelioma
This may implicate a difference in Bax functioning in erionite induced MPM. However, Fas Ligand may be functionally intact to reduce tumor survival.
November 21st, 2005. Cisplatin-Induced GADD34 Upregulation Potentiates Oncolytic Viral Therapy in the Treatment of Malignant Pleural Mesothelioma
Conclusion: Cisplatin-induced GADD34 expression selectively enhanced the cytotoxicity of the gamma(1)34.5-deficient oncolytic virus, NV1066. This provides a cellular basis for combination therapy with cisplatin and NV1066 to treat MPM and achieve synergistic efficacy, while minimizing dosage and toxicity.
Posted in Biphasic or Mixed, Chemotherapy, Cisplatin (Platinol ®), Epithelioid, Full Archive, Gene Therapy, New & Novel, Sarcomatoid, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
November 21st, 2005. Use of imaging in the management of malignant pleural mesothelioma
In view of its pattern of growth, MPM is a challenging disease to image by any method, and it behaves quite differently from lung cancer. This review aims to highlight the practical aspects of assessing malignant pleural mesothelioma.
November 21st, 2005. Pemetrexed: A multitargeted antifolate
Conclusions: Pemetrexed is a multitargeted antifolate that has demonstrated antitumor activity in various tumor types as a single agent and
November 21st, 2005. Pemetrexed: a new cytotoxic agent in the development for first-line non-small-cell lung cancer
Dietary supplementation with low-dose folic acid and vitamin B12 significantly reduces the incidence and severity of toxicities without compromising the antitumor activity of pemetrexed. With its innovative mode of action, proven efficacy, favorable toxicity profile and convenient administration, pemetrexed represents a new therapeutic option for the treatment of advanced NSCLC.
November 21st, 2005. Standard therapy for the treatment of malignant pleural mesothelioma
In particular, pemetrexed produces response rates of up to 45%, and increases median survival to over 12 months when used in combination with cisplatin. This doublet-based chemotherapy regimen is now the standard therapy for the first-line treatment of MPM.
November 21st, 2005. Seeking new options for the treatment of small-cell lung cancer
With an excellent antitumor activity, favorable tolerability profile, ease of administration and convenient schedule in NSCLC patients, pemetrexed is currently being investigated in a phase II trial for the first-line treatment of ES SCLC. Observations from this trial will help to define the future role of pemetrexed in SCLC.
November 21st, 2005. Perspective on the development of new agents in thoracic cancers
Inhibitors of the epidermal growth factor receptor (EGFR) are one of many promising targeted therapies for non-small-cell lung cancer (NSCLC). By utilizing agents that specifically target the biochemical and molecular changes underlying cancer, it is possible to envision a future in which combinations of therapies treat cancer on multiple fronts, significantly enhancing tumor responses and improving survival beyond current expectations.
November 18th, 2005. Moving knowledge of global burden into preventive action
Conclusions: The magnitude of the occupational health burden in the world is overwhelming, and the causes and mechanisms are multiple and complex. Commitment from all stakeholders is imperative to translate economic progress into sustainable human development and well-being.
November 18th, 2005. Asbestos-related pleuropulmonary diseases: Pictorial essay
Some neoplasias, like lung carcinoma and pleural mesothelioma, are more prevalent in asbestos-exposed subjects. The aim of this essay is to illustrate the main imaging findings of asbestos-related diseases.
November 16th, 2005. Partial, but not Complete, Tumor-Debulking Surgery Promotes Protective Antitumor Memory when Combined with Chemotherapy and Adjuvant Immunotherapy
Partial debulking followed by combination therapy elicited the same proportion of cured animals but in contrast to complete resection, a memory response was invoked. We postulate that chemotherapy induced apoptosis of the residual tumor cells following incomplete resection is absolutely required for the induction of long-term immunologic memory.
November 16th, 2005. Update on malignant mesothelioma
The median survival is under a year, although longer median survivals for selected patients, particularly those with epithelial histology, have been reported in some combined-modality studies. Recent randomized trials have shown significant improvement in time to progression and survival for the addition of new antifolates to platinum-based chemotherapy.
November 7th, 2005. Prolonged survival after talc poudrage for malignant pleural mesothelioma: Case series
Conclusion: TTP remains a safe, low-morbidity, inexpensive primary palliative treatment option for malignant pleural mesothelioma and a valid control arm option for therapeutic trials. TTP is ideal for patients who wish to avoid thoracotomy, long hospital stays and morbidity from multimodality therapy. Prospective randomized studies are needed to compare quality of life and survival after talc poudrage and other therapies.
November 7th, 2005. Clinicopathological analysis of lung cancer resembling malignant pleural mesothelioma.
Conclusions: Lung cancer resembling malignant pleural mesothelioma is most frequently observed in patients with adenocarcinoma, which is suspected to occur peripherally. To distinguish pseudomesotheliomatous carcinoma from malignant pleural mesothelioma in patients with diffuse pleural thickening and effusion, requires adequate tissue sampling by thoracotomy or video-assisted thoracoscopic surgery and a panel of immunohistochemical stains.
|
|  |
